Hugo Hool

485 total citations
3 papers, 20 citations indexed

About

Hugo Hool is a scholar working on Oncology, Biotechnology and Infectious Diseases. According to data from OpenAlex, Hugo Hool has authored 3 papers receiving a total of 20 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Oncology, 1 paper in Biotechnology and 0 papers in Infectious Diseases. Recurrent topics in Hugo Hool's work include Cancer Immunotherapy and Biomarkers (2 papers), HER2/EGFR in Cancer Research (2 papers) and Cancer Treatment and Pharmacology (2 papers). Hugo Hool is often cited by papers focused on Cancer Immunotherapy and Biomarkers (2 papers), HER2/EGFR in Cancer Research (2 papers) and Cancer Treatment and Pharmacology (2 papers). Hugo Hool collaborates with scholars based in United States. Hugo Hool's co-authors include Vincent J. Picozzi, John H. Strickler, Lei Zhou, Irfan Firdaus, Noelle K. LoConte, Ann M. Kapoun, Eric Holmgren, Ravindranath Patel, Andrea J. Bullock and Paul S. Ritch and has published in prestigious journals such as Journal of Clinical Oncology.

In The Last Decade

Hugo Hool

3 papers receiving 20 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hugo Hool United States	2	18	10	6	3	2	3	20
J. Leigh Fantacone-Campbell United States	4	12 0.7×	9 0.9×	7 1.2×	3 1.0×	1 0.5×	5	25
Lidia Estudillo Spain	2	16 0.9×	13 1.3×	8 1.3×	2 0.7×	5 2.5×	3	21
Abraham Tzou United States	1	13 0.7×	10 1.0×	5 0.8×	3 1.0×	3 1.5×	2	26
Rim S. Kim United States	4	22 1.2×	7 0.7×	3 0.5×	4 1.3×	3 1.5×	7	25
Fumihiko Urushibara Japan	2	13 0.7×	7 0.7×	8 1.3×	5 1.7×	3 1.5×	3	25
Nils Rouven Hansmeier Germany	4	8 0.4×	7 0.7×	9 1.5×	2 0.7×	3 1.5×	5	27
Elvire Roblin France	2	12 0.7×	6 0.6×	4 0.7×	2 0.7×	3 1.5×	5	23
Diane Heditsian United States	3	7 0.4×	8 0.8×	7 1.2×	3 1.0×		11	20
Tomonari Cho Japan	2	14 0.8×	7 0.7×	8 1.3×	5 1.7×	3 1.5×	3	25
TO Nielsen Canada	3	18 1.0×	14 1.4×	6 1.0×		2 1.0×	9	25

Countries citing papers authored by Hugo Hool

Since Specialization

Citations

This map shows the geographic impact of Hugo Hool's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hugo Hool with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hugo Hool more than expected).

Fields of papers citing papers by Hugo Hool

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hugo Hool. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hugo Hool. The network helps show where Hugo Hool may publish in the future.

Co-authorship network of co-authors of Hugo Hool

This figure shows the co-authorship network connecting the top 25 collaborators of Hugo Hool. A scholar is included among the top collaborators of Hugo Hool based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hugo Hool. Hugo Hool is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

3 of 3 papers shown

1.

McArthur, Heather L., Stephen L. Shiao, Reva Basho, et al.. (2023). Neoadjuvant HER2-targeted therapy ± immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial.. Journal of Clinical Oncology. 41(16_suppl). TPS634–TPS634. 1 indexed citations

2.

McArthur, Heather L., David B. Page, Reva Basho, et al.. (2022). Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open-label randomized phase II trial.. Journal of Clinical Oncology. 40(16_suppl). TPS624–TPS624. 3 indexed citations

3.

O’Reilly, Eileen M., Vaibhav Sahai, Johanna C. Bendell, et al.. (2017). Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).. Journal of Clinical Oncology. 35(4_suppl). 279–279. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact